Dr Reddy's Laboratories (BSP:R1DY34) Total Stockholders Equity : R$15,764 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Dr Reddy's Laboratories Total Stockholders Equity?

Dr Reddy's Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was R$15,764 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Dr Reddy's Laboratories's Book Value per Share for the quarter that ended in Dec. 2023 was R$15.78. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Dr Reddy's Laboratories's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.07.

Dr Reddy's Laboratories Total Stockholders Equity Historical Data

The historical data trend for Dr Reddy's Laboratories's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Total Stockholders Equity Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

7,748.72

10,158.56

13,392.30

12,444.46

14,624.91

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															14,009.54	14,624.91	14,477.54	15,046.54	15,763.94

Dr Reddy's Laboratories (BSP:R1DY34) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Dr Reddy's Laboratories's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(15763.944	-	0)	/	999.08
	=	15.78

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Dr Reddy's Laboratories's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(806.236	+	362.068)	/	15763.944
	=	0.07

Dr Reddy's Laboratories Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (BSP:R1DY34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (BSP:R1DY34) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany RDDA:Germany

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (BSP:R1DY34) Headlines

No Headlines